The U.S. Food and Drug Administration (FDA) granted accelerated approval for Trodelvy, a drug therapy for patients with locally advanced or metastatic urothelial cancer (mUC), an aggressive disease with a survival rate of 5.5%. Previously, Trodelvy was granted accelerated approval by the FDA for adult patients with metastatic triple-negative breast cancer (mTNBC), granted that they had received two prior therapies for metastatic disease. Trodelvy was aquired by Gilead through its $21 billion USD acquisition of Immunomedics, and is expected to be a fundamental drug therapy for Gilead’s oncology business unit.

Read more here.

More on: